Entering text into the input field will update the search result below

J&J Q3 top line off 7%; net income down 29%; full-year EPS guidance raised

Oct. 13, 2015 8:06 AM ETJohnson & Johnson (JNJ) StockBy: Douglas W. House, SA News Editor8 Comments
  • Johnson & Johnson (NYSE:JNJ) Q3 results ($M): Total Revenues: 17,102 (-7.4%); Consumer: 3,314 (-7.7%); Pharmaceutical: 7.694 (-7.4%); Medical Devices & Diagnostics: 6,094 (-7.3%).
  • Revenues by Region: U.S.: 8,791 (-0.6%); Europe: 3,802 (-14.5%); W. Hemisphere ex-U.S.: 1,463 (-19.6%); Asia Pacific & Africa: 3,046 (-9.3%).
  • Net Income: 3,358 (-29.3%); EPS: 1.20 (-27.7%); Non-GAAP EPS: 1.49 (-0.7%).
  • Key Product Sales: Remicade: 1,613 (-9.5%); Stelara: 613 (+12.9%); Invega Sustenna/Xeplion: 459 (+13.9%); Zytiga: 548 (-3.5%); Xarelto: 461 (+11.4%); Invokana/Invokamet: 340 (+392.8%).
  • 2015 Guidance: EPS: $6.15 - 6.20 from $6.10 - 6.20.

Recommended For You

About JNJ Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
JNJ--
Johnson & Johnson